Abstracts tagged "APL"

Abstract Number: 1963 • 2016 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevated in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Free Active TGF-b1 Levels, IL-1b and IL-17A
Markos Patsouras, Athanasios G. Tzioufas and Panayiotis G Vlachoyiannopoulos, School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein secreted by platelets upon…
Abstract Number: 2100 • 2016 ACR/ARHP Annual Meeting
Pharmaceutical Disruption of B2GPI CXCL4 Complex Using Computationally Designed Oligopeptides
Markos Patsouras¹, Elenh Papakonstantinou², Elias Eliopoulos² and Panayiotis G Vlachoyiannopoulos¹, ¹School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece, ²Department of Biotechnology, Agricultural University of Athens, ATHENS, Greece
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by recurrent thromboembolism and or pregnancy morbidity in the presence of antiphospholid antibodies (aPL). Major auto…
Abstract Number: 2536 • 2015 ACR/ARHP Annual Meeting
The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl
Sancia Ferguson¹, Elianna Kaplowitz², Laura Trupin³, Edward H. Yelin⁴, Patricia P. Katz^3,5 and Jane E. Salmon⁶, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²Hospital for Special Surgery, New York, NY, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA, ⁵Arthritis Research Group, University of California San Francisco, San Francisco, CA, ⁶Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibodies (aPL) have pregnancies with higher rates of preterm labor, preeclampsia, and fetal loss than healthy…
Abstract Number: 1082 • 2014 ACR/ARHP Annual Meeting
Risk of Intra Cranial Hemorrhage among Patients with Anti-Phospho-Lipid-Antibody (aPL) syndrome vs Systemic Lupus Erythematosus (SLE) in Stroke Population: A Nationwide Analysis
Tapan Mehta¹, Khushboo Sheth², Ronak Soni³, Sonam Puri² and Kathan Mehta⁴, ¹Neurology, University of Connecticut, Farmington, CT, Farmington, CT, ²Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ³Internal Medicine, Government Medical College, Surat, India, ⁴Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, Pittsburgh, PA
Background/Purpose Central nervous system involvement is common in Systemic Lupus Erythematosus (SLE) and was first described in 1873. Though ischemic involvement is more common than…
Abstract Number: 1081 • 2014 ACR/ARHP Annual Meeting
Prediction of Mortality Risk Related to Cerebrovascular Accidents in Patients with Systemic Lupus Erythematosus (SLE) vs Anti-Phospho-Lipid-Antibody (aPL) syndrome
Khushboo Sheth¹, Tapan Mehta², Sonam Puri¹, Ronak Soni³ and Kathan Mehta⁴, ¹Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ²Neurology, University of Connecticut, Farmington, CT, Farmington, CT, ³Internal Medicine, Government Medical College, Surat, India, ⁴Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, Pittsburgh, PA
Background/Purpose : It is well-established that patients with co-existent Systemic Lupus Erythematosus (SLE) and Anti-Phospho-Lipid-Antibody (aPL) syndrome are at increased risk of cerebrovascular accidents (CVA).…
Abstract Number: 2552 • 2013 ACR/ARHP Annual Meeting
Predictive Significance Of ANTI-Prothrombin Antibodies For Second and Third Trimester Obstetric Complications In Patients With Systemic LUPUS Erythematosus and ANTI-Phospholipid Syndrome
Marta Mosca¹, Chiara Tani², Martina Fabris³, Francesca Strigini⁴, Linda Carli¹, Sabrina Vagnani⁵, Rosaria Talarico⁶, Chiara Baldini⁷, Alessandra Della Rossa⁸, Elio Tonutti⁹ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Institute of Clinical Pathology, Udine, Italy, ⁴University of Pisa, Pisa, Italy, ⁵Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁶Rheumatology Unit, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁹Santa Maria Hospital, Udine, Italy
Background/Purpose: Anti-prothrombin antibodies (aPT) either alone or in association with other anti-phospholipid antibodies have been associated with an increased risk of thrombosis as well as…
Abstract Number: 22 • 2013 ACR/ARHP Annual Meeting
WHAT Is The Prevalence Of NON CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN Patients With Antiphospholipid Syndrome?
Veronica Rodriguez-Garcia¹, Yiannis Ioannou², D.a. Isenberg³ and Ian Giles⁴, ¹rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Increasing interest has focussed upon assays which are not currently included in the Antiphospholipid syndrome (APS) classification criteria to detect antibodies directed against other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].